Cancer BiologybioRxivPreprint
Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma
S. S. Schalm, E. O'Hearn, K. Wilson…·K. P. Hoeflich
This study evaluates PRKACA as a therapeutic target for fibrolamellar carcinoma using PDX models and shows that its knockdown or inhibition reduces tumor growth.
DOI 10.1101/2022.01.31.477690